Lakewood-Amedex Biotherapeutics announces positive preclinical data for urinary and pulmonary infections
Preclinical results and a stated timeline for Phase 2a topline data could influence expectations for future clinical development.
Oct. 7 - Lakewood-Amedex Biotherapeutics Inc said it has positive preclinical data for urinary tract and pulmonary infection indications with its Bisphosphocin compounds. The company also said topline data from the Bisphosphocin Nu-3 Phase 2a trial is expected in Q1 2027.